摘要
急性冠脉综合征(acute coronary syndrome,ACS)患者通常需接受经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)。手术前一般给予患者氯吡格雷以发挥抗血小板功能,但由于目前市场中仅存在氯吡格雷片,而口服起效时间较长,易于错失临床最佳治疗时机。因此,研制氯吡格雷注射剂型具有重要意义,不仅可以为急性冠脉综合征患者治疗提供一种更灵活、有效的用药选择,还可以提高急诊经皮冠状动脉介入治疗手术的成功率,降低患者血栓发生率和死亡风险。本文综述了近年来氯吡格雷注射剂的研发进展,重点讨论了相关注射剂型的技术特点和应用前景,为氯吡格雷注射剂的研发提供参考。
Patients suffering acute coronary syndrome(ACS)usually need to receive percutaneous coronary intervention(PCI).Clopidogrel is generally given to patients before operation to exert antiplatelet function.However,there is only Clopidogrel Tablets in the market at present,and the onset time is too long so that it is easy to miss the optimum therapeutic time.Therefore,it is urgent to develop an injectable clopidogrel formulation for clinical application.Once marketed,it can not only provide a more flexible and effective option for patients with ACS,but also improve the success rate of emergency PCI and reduce the incidence of thrombosis and the risk of death.In this review,we introduced the progress of Clopidogrel Injections,briefly discuss their technical features,and provided references for the research and development of Clopidogrel Injections.
作者
王雪怡
孙平平
孙春萌
涂家生
WANG Xueyi;SUN Pingping;SUN Chunmeng;TU Jiasheng(NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients,Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs,Department of Pharmaceutics,School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China)
出处
《药学研究》
CAS
2022年第1期37-41,共5页
Journal of Pharmaceutical Research
基金
国家自然科学基金项目(面上项目、重点项目、重大项目)(No.81972894、81673364)。
